Filing Flows › DexCom (DXCM) › Guidance history
DexCom (DXCM) guidance history: what it guided and what it reported
DexCom gave guidance in 12 earnings releases on file since Jul 25, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +0.3% against the guided midpoint. Its releases raised guidance 5 times and lowered it 0 times.
Revenue
Met or beat 2 of 2 periods (1 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $5.2B–$5.2B (Jan 12, 2026) → reaffirmed $5.2B–$5.2B (Feb 12, 2026) → reaffirmed $5.2B–$5.2B (Apr 30, 2026) → reaffirmed $5.2B–$5.2B (Jul 30, 2026) → reaffirmed $5.2B–$5.2B (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $4.6B (Jan 13, 2025) → reaffirmed $4.6B (Feb 13, 2025) → raised $4.6B–$4.6B (Jul 30, 2025) → raised $4.6B–$4.7B (Oct 30, 2025) | $4.7B | above the range | +0.5% |
| FY2024 | $4.0B–$4.0B (Oct 24, 2024) | $4.0B | within the range | +0.2% |
| Q3 2024 | $975M–$1.0B (Jul 25, 2024) | — | — | — |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 63.0%–64.0% (Jan 12, 2026) → reaffirmed 63.0%–64.0% (Feb 12, 2026) → reaffirmed 63.0%–64.0% (Apr 30, 2026) → raised 64.0% (Jul 30, 2026) → reaffirmed 64.0% (Oct 29, 2026) | — | to be reported | — |
| FY2025 | 64.0%–65.0% (Jan 13, 2025) → reaffirmed 64.0%–65.0% (Feb 13, 2025) → lowered 62.0% (Jul 30, 2025) → lowered 61.0% (Oct 30, 2025) | — | — | — |
| FY2024 | 63.0% (Oct 24, 2024) | — | — | — |
Adjusted operating margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 22.0%–23.0% (Jan 12, 2026) → reaffirmed 22.0%–23.0% (Feb 12, 2026) → raised 23.0%–23.5% (Apr 30, 2026) → raised 23.5%–24.0% (Jul 30, 2026) → raised 24.0% (Oct 29, 2026) | — | to be reported | — |
| FY2025 | 21.0% (Jan 13, 2025) → reaffirmed 21.0% (Feb 13, 2025) → reaffirmed 21.0% (Jul 30, 2025) → lowered 20.0%–21.0% (Oct 30, 2025) | — | — | — |
| FY2024 | 20.0% (Oct 24, 2024) | — | — | — |
Adjusted EBITDA margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 30.0%–31.0% (Feb 12, 2026) → raised 31.0%–31.5% (Apr 30, 2026) → raised 31.5%–32.0% (Jul 30, 2026) → raised 32.0% (Oct 29, 2026) | — | to be reported | — |
| FY2025 | 30.0% (Feb 13, 2025) → reaffirmed 30.0% (Jul 30, 2025) → lowered 29.0%–30.0% (Oct 30, 2025) | — | — | — |
| FY2024 | 29.0% (Oct 24, 2024) | — | — | — |
The latest quarter
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
Questions
Does DexCom beat its guidance?
DexCom gave guidance in 12 earnings releases on file since Jul 25, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +0.3% against the guided midpoint.
How often does DexCom raise guidance?
Its earnings releases raised guidance 5 times and lowered it 0 times since Jul 25, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.